IRLAB Therapeutics (IRLAB) Q2 2024 earnings summary

Executive summary

• Achieved significant milestones in Q2 2024, including initiation of Phase I for IRL757, advancement of mesdopetam and pirepemat programs, and appointment of Kristina Torfgård as CEO effective August 1, 2024.

• Entered a major collaboration with MSRD/Otsuka for IRL757, securing full funding through clinical proof-of-concept, with $3M upfront and $8.5M in near-term payments.

• Phase 2b REACT PD study for pirepemat received unanimous DSMB support to continue, with patient recruitment expected to complete in Q3 2024 and top-line data in Q1 2025.

• Business development activities intensified, with ongoing partnership discussions and increased industry awareness, especially for mesdopetam.

• Received strong external validation and financial support from The Michael J. Fox Foundation.

Financial highlights

• Net sales for Jan–Jun 2024 were SEK 42.8M, up from SEK 6.9M year-over-year, driven by research collaborations and licensing.

• Operating loss narrowed to SEK -42.7M from SEK -104.4M year-over-year; loss for the period was SEK -46.1M.

• Cash and cash equivalents at June 30, 2024 were SEK 98.3M, down from SEK 156.4M a year earlier.

• Cash flow from operating activities improved to SEK -38.1M from SEK -94.3M year-over-year.

• Drew SEK 25M from Fenja Capital loan facility to support operations.

Outlook and guidance

• Multiple value-creating milestones expected in the next 12–18 months, including Phase 3 start for mesdopetam, completion of pirepemat Phase 2b, and advancement of preclinical assets IRL942 and IRL1117.

• Ongoing business development and potential partnerships could influence funding and operational strategies for late-stage programs.